Please use this identifier to cite or link to this item:
|Title:||Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma|
|Authors:||Chew, P.T.K. |
|Source:||Chew, P.T.K., Aung, T., Aquino, M.V., Rojanapongpun, P. (2004). Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma. Ophthalmology 111 (3) : 427-434. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ophtha.2003.06.007|
|Abstract:||Objective: To demonstrate that the intraocular pressure (IOP)-reducing effect of latanoprost once daily is at least as good as that of timolol twice daily in patients with chronic angle-closure glaucoma (CACG). Design: Randomized, double-masked, multicenter 12-week study. Participants: In all, 137 patients with unilateral or bilateral CACG were treated with latanoprost, and 138 were treated with timolol. Methods: Patients received either latanoprost (9 PM) and a placebo (9 AM) or timolol (both 9 AM and 9 PM). Intraocular pressure was measured at 9 AM and 5 PM at baseline and weeks 2, 6, and 12. Main Outcome Measures: The difference between groups in daily IOP (average of 9 AM and 5 PM measures) reduction was the primary outcome. Secondary outcomes included differences between groups in IOP reductions at 9 AM and 5 PM, and in proportions of patients reaching specified daily IOP levels. Results: Using repeated measures (analysis of covariance: intent to treat), mean changes from baseline in daily IOP levels during 12 weeks were -8.2 mmHg and -5.2 mmHg for latanoprost- and timolol-treated patients, respectively (difference: -3.0 mmHg [95% confidence interval: -4.0, -2.1], P<0.001). Greater reductions in IOP levels at both 9 AM and 5 PM were found in latanoprost-treated patients (P<0.001 for both), and greater proportions of patients receiving latanoprost reached prespecified target daily IOP levels (P<0.001 for all 3 target levels tested). Both drugs were well tolerated. Conclusion: Latanoprost administered once daily provides significantly greater IOP reduction in CACG patients than does timolol instilled twice daily. © 2004 by the American Academy of Ophthalmology.|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Feb 26, 2018
WEB OF SCIENCETM
checked on Feb 26, 2018
checked on Feb 25, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.